MAPT and early-onset autosomal dominant Alzheimer disease: In a streptozotocin-induced rat model of Alzheimer’s disease, saxaglitpin and vildagliptin decreased amyloid-β deposition and tau phosphorylation by increasing hippocampal glucagon-like peptide-1 levels, which reversed the cognitive deficits [11,12].